Six peptides dominate the gut health conversation in 2026: BPC-157 for tissue repair, KPV for inflammation control, larazotide for tight junction restoration, colostrum peptides for immunological support, GLP-2 for epithelial growth, and LL-37 for antimicrobial defense. The evidence behind each varies from FDA-approved (teduglutide, a GLP-2 analog for short bowel syndrome) to entirely preclinical (LL-37 for gut applications). This guide grades every option by the quality of its evidence and maps each peptide to specific gut conditions.
A note on terminology. Peptides are short chains of amino acids, typically 2 to 50 amino acids long, that function as signaling molecules. They are smaller than proteins and far smaller than biologics. The body produces thousands of endogenous peptides that regulate digestion, immune function, and tissue repair. Therapeutic peptides are synthetic versions of these molecules designed to amplify specific biological effects.
How Peptides Repair the Gut: 3 Mechanisms
Gut peptides work through three distinct pathways. Understanding which mechanism each peptide uses matters because it determines which gut condition it is best suited for.
Tissue Repair
BPC-157 and GLP-2 promote structural healing of damaged intestinal tissue. BPC-157 stimulates angiogenesis (new blood vessel formation) by upregulating vascular endothelial growth factor (VEGF) and modulating the nitric oxide (NO) system. New blood supply to damaged mucosa accelerates repair. GLP-2 works differently: it stimulates crypt cell proliferation and increases villus height, directly expanding the absorptive surface area of the intestine.
These mechanisms matter most when the gut lining is physically damaged, as in ulcers, NSAID-induced injury, surgical anastomosis, or the mucosal erosion seen in Crohn's disease.
Inflammation Control
KPV and colostrum peptides target the inflammatory cascades that perpetuate gut damage. KPV, a three-amino-acid fragment of alpha-melanocyte stimulating hormone (alpha-MSH), inhibits nuclear factor kappa B (NF-kB), the master switch for inflammatory gene expression. When NF-kB activation is blocked, downstream production of TNF-alpha, IL-6, and IL-1beta drops. KPV enters intestinal epithelial cells through the PepT1 transporter, which means it works directly inside the cells lining the gut.
Colostrum provides a broader anti-inflammatory toolkit: lactoferrin, immunoglobulins (IgG, IgA), and growth factors (IGF-1, TGF-beta) that support mucosal immunity without stimulating autoimmune pathways.
Barrier Restoration
Larazotide acetate and LL-37 address the "leaky gut" problem directly. Larazotide blocks the zonulin receptor on intestinal epithelial cells. Zonulin, identified by Alessio Fasano's research group, is a protein that opens tight junctions between intestinal cells. By antagonizing zonulin, larazotide keeps those junctions sealed and prevents the translocation of undigested food proteins, bacteria, and endotoxin into the bloodstream.
LL-37, a cathelicidin antimicrobial peptide, takes a different approach to barrier defense. It disrupts bacterial membranes, breaks down biofilms, and modulates immune cell recruitment. When dysbiosis drives gut inflammation, LL-37 addresses the microbial component.
The 6 Best Peptides for Gut Health
1. BPC-157: Tissue Repair and Cytoprotection (Grade B-)
Body Protection Compound 157 is a 15-amino-acid peptide originally isolated from human gastric juice. It has the largest body of preclinical evidence for gut healing of any peptide, spanning over 100 animal studies across three decades of research by Predrag Sikiric's group at the University of Zagreb.
Mechanism. BPC-157 promotes angiogenesis through VEGF and fibroblast growth factor (FGF) upregulation. It modulates the NO system, which controls blood flow and inflammation in the gut. It also supports tight junction proteins and reduces oxidative stress at the mucosal surface.
Evidence. The animal data is remarkably consistent. BPC-157 accelerated healing in ethanol-induced gastric ulcers, NSAID-induced intestinal damage, TNBS and DSS colitis models (standard preclinical models for Crohn's and UC), esophageal lesions, and intestinal fistulas. In the fistula model, complete closure occurred in treated animals while controls showed persistent tracts. The grade is B- rather than C because the preclinical evidence is unusually deep and consistent across multiple damage models. The critical limitation: no human randomized controlled trial has ever been conducted.
Best for. Leaky gut, NSAID-induced damage, IBD (adjunct), ulcers, fistulas.
Dosing. Practitioner protocols typically use 250 to 500 mcg twice daily, taken orally on an empty stomach. BPC-157 is stable in gastric acid, unlike most peptides, which makes oral administration viable. Cycles of 4 to 8 weeks are common, followed by 2 to 4 weeks off.
Access. Following the February 2026 FDA reclassification, BPC-157 is now legally compoundable as a Category 1 compound. It is available through compounding pharmacies with a prescription. It is not FDA-approved for any indication. WADA has prohibited it since 2022 for competitive athletes.
For a full deep-dive, see our BPC-157 for gut healing guide.
2. KPV: Anti-Inflammatory Tripeptide (Grade C+)
KPV consists of just three amino acids (lysine-proline-valine) from positions 11 through 13 of alpha-MSH. Despite its small size, it retains the potent anti-inflammatory properties of its parent hormone without causing skin darkening (melanogenesis).
Mechanism. KPV inhibits NF-kB translocation to the nucleus by entering intestinal epithelial cells through the PepT1 peptide transporter. Once inside, it suppresses the inflammatory gene expression that drives cytokine production. This is the same pathway targeted by many IBD drugs, but through a different molecular entry point.
Evidence. Kannengiesser et al. (2008, PMID 18061177) demonstrated that KPV reduced DSS-induced colitis severity by roughly 50% in mice, with significant reduction in inflammatory markers. Xiao et al. (2017, PMC5498804) showed that KPV-loaded nanoparticles delivered to the colon reduced colitis severity and promoted mucosal healing in a mouse model. The nanoparticle delivery study is notable because it addresses the bioavailability challenge inherent to oral peptide administration. The grade is C+ because the evidence, while promising, consists of only two major animal studies with no human trial data.
Best for. Ulcerative colitis, IBD-related gut inflammation, conditions driven by NF-kB overactivation.
Dosing. Practitioner protocols range from 200 to 500 mcg per day, administered orally or by subcutaneous injection. Oral bioavailability is uncertain without nanoparticle formulation.
Access. KPV was reclassified as Category 1 in February 2026 and is now legally compoundable. Available through compounding pharmacies with a prescription.
For full mechanism and evidence details, see our KPV peptide guide.
3. Larazotide Acetate: Zonulin Antagonist (Grade B for Celiac, Grade C for General Leaky Gut)
Larazotide acetate (also known as AT-1001) is the only peptide designed specifically to target intestinal permeability. It works as a zonulin antagonist, directly blocking the receptor that opens tight junctions between intestinal epithelial cells. The zonulin pathway, characterized by Alessio Fasano's research, is now recognized as a key mechanism linking gut permeability to autoimmune disease.
Mechanism. Zonulin is released in response to triggers like gliadin (a gluten protein) and certain gut bacteria. When zonulin binds to its receptor on epithelial cells, it disassembles the tight junction proteins claudin, occludin, and zonula occludens-1 (ZO-1). Larazotide competes for that receptor binding site, preventing tight junction disassembly and keeping the intestinal barrier intact.
Evidence. The Phase 2b trial (Leffler et al. 2015, published in Gastroenterology) tested larazotide in celiac patients on a gluten-free diet who still had persistent symptoms. The 0.5 mg dose significantly reduced symptoms compared to placebo. This was a properly powered, multicenter, randomized controlled trial with a clear positive signal.
The Phase 3 CedLara trial, sponsored by 9 Meters Biopharma, was discontinued in 2022. This requires honest context. The trial did not fail because of safety concerns or because the drug did not work. The issues were statistical: the primary endpoint was difficult to measure reliably, and the trial was likely underpowered for the effect size. The mechanism itself remains validated. Zonulin is real, its role in intestinal permeability is well-established, and the Phase 2b data showed a genuine therapeutic signal.
For celiac patients on a strict gluten-free diet who still experience symptoms (a common and frustrating problem), larazotide remains the most mechanistically targeted option available. For general "leaky gut" outside of celiac disease, the evidence grade drops to C because the clinical data was specific to celiac patients.
Best for. Celiac disease (persistent symptoms on GFD), gluten-induced intestinal permeability.
Access. Larazotide is not commercially available. It can be obtained through research suppliers and some compounding pharmacies, but there is no standard pharmaceutical product. This is not an over-the-counter supplement.
4. Colostrum Peptides: Immunological Support (Grade B)
Bovine colostrum is the oldest "peptide therapy" on this list and the most accessible. It is the first milk produced by cows after birth, rich in bioactive peptides, immunoglobulins, and growth factors. Unlike the other peptides here, colostrum is available over the counter as a dietary supplement with no prescription required.
Mechanism. Colostrum contains multiple bioactive components relevant to gut healing. Lactoferrin binds iron (starving pathogenic bacteria) and has direct anti-inflammatory effects. Immunoglobulins IgG and IgA provide passive immune support at the mucosal surface. Growth factors IGF-1 and TGF-beta promote epithelial cell proliferation and wound healing. Proline-rich polypeptides (PRPs) modulate immune function, helping to balance overactive immune responses.
Evidence. Playford et al. (2001) demonstrated that bovine colostrum reduced NSAID-induced intestinal permeability in a human study. This is significant because it provides the human data that most other gut peptides lack. Additional studies have shown colostrum reduces gut permeability in athletes undergoing heat stress (a model for exercise-induced leaky gut) and supports mucosal recovery after gastrointestinal infections. The evidence grade of B reflects the presence of human data, though the studies are smaller than ideal and the colostrum product is a complex mixture rather than a single compound.
Best for. General gut integrity support, NSAID-induced damage, immune support, exercise-induced gut permeability.
Dosing. 5 to 20 grams of bovine colostrum daily, typically taken on an empty stomach. Higher doses (15 to 20 grams) are used in the initial healing phase, tapering to 5 to 10 grams for maintenance. Look for products standardized to immunoglobulin content (at least 25% IgG).
Access. Widely available OTC. No prescription required. This is the most accessible option on this list and a reasonable starting point for anyone considering gut peptide therapy.
5. GLP-2 (Teduglutide): Epithelial Growth (Grade A for Short Bowel Syndrome)
Glucagon-like peptide 2 (GLP-2) is an endogenous hormone produced by L-cells in the ileum and colon. Teduglutide (brand name Gattex) is a synthetic GLP-2 analog with a longer half-life, and it is the only gut peptide on this list with FDA approval.
Mechanism. GLP-2 stimulates crypt cell proliferation, increases villus height, reduces crypt cell apoptosis, and enhances nutrient absorption. It promotes intestinal mucosal growth through a receptor-mediated pathway that directly expands the functional surface area of the small intestine. It also increases mesenteric blood flow and reduces intestinal inflammatory cytokines (Drucker 2005).
Evidence. Teduglutide received FDA approval in 2012 for short bowel syndrome (SBS) in adults dependent on parenteral nutrition. The approval was based on multiple randomized controlled trials showing significant reduction in parenteral nutrition requirements. This is Grade A evidence: multiple RCTs, FDA regulatory review, and sustained clinical benefit.
The limitation is specificity. Teduglutide is approved and studied for SBS, a condition where large portions of the small intestine have been surgically removed. Its relevance to IBD, leaky gut, or general gut healing is theoretical. Some preclinical data suggests GLP-2 has anti-inflammatory effects in IBD models, but this has not translated into approved clinical use for IBD.
Best for. Short bowel syndrome (FDA-approved indication). Theoretical relevance to IBD and intestinal adaptation.
Dosing. 0.05 mg/kg subcutaneous injection once daily (prescription only). This is a pharmaceutical product, not a compounding pharmacy peptide.
Access. Prescription only. Expensive (estimated annual cost exceeds $300,000). Available only through specialty pharmacies for the approved SBS indication. Not a practical option for general gut health.
Natural GLP-2 support. Endogenous GLP-2 production can be increased through dietary fiber (short-chain fatty acid production stimulates L-cells), specific probiotics (Akkermansia muciniphila, Lactobacillus rhamnosus), and adequate caloric intake. This is not equivalent to pharmaceutical teduglutide but is a free, risk-free intervention worth noting.
6. LL-37: Antimicrobial Barrier Defense (Grade C)
LL-37 is a 37-amino-acid cathelicidin peptide produced by immune cells, epithelial cells, and Paneth cells in the small intestine. It is the body's frontline antimicrobial defense peptide, and its deficiency has been linked to impaired gut barrier function and susceptibility to intestinal infections.
Mechanism. LL-37 disrupts bacterial cell membranes through direct electrostatic interaction with the lipid bilayer. It also breaks down bacterial biofilms, which are communities of bacteria encased in protective matrices that resist antibiotics. Beyond antimicrobial activity, LL-37 modulates immune cell chemotaxis (recruiting neutrophils and macrophages to sites of infection) and promotes wound healing in epithelial tissue.
Evidence. The evidence for LL-37 in gut health is primarily mechanistic. Studies on Paneth cell dysfunction in Crohn's disease show that impaired antimicrobial peptide production (including LL-37 and defensins) contributes to ileal dysbiosis and mucosal inflammation. Vitamin D directly regulates LL-37 gene expression, which provides a mechanistic link between vitamin D deficiency and impaired gut barrier defense. However, no study has tested exogenous LL-37 administration for any gut condition in humans or animals.
Best for. Dysbiosis-driven gut inflammation, post-antibiotic gut repair (theoretical), conditions involving impaired antimicrobial defense.
Dosing. No established protocol exists. LL-37 is available as a research compound. Practitioner protocols vary widely and are not based on clinical data.
Access. Research compound only. Not available through standard compounding pharmacies. Not FDA-approved or reclassified under Category 1.
Alternative approach. Boosting endogenous LL-37 production through vitamin D optimization (target serum 25-OH-D of 50 to 70 ng/mL) and butyrate supplementation may be more practical and evidence-based than exogenous LL-37 administration. For more on LL-37 in autoimmune contexts, see our LL-37 peptide guide.
Which Peptide for Which Gut Condition?
Choosing the right peptide depends on the primary driver of your gut problem. Tissue damage calls for BPC-157. Active inflammation calls for KPV. Permeability-specific issues call for larazotide. Here is a condition-by-condition breakdown.
Leaky gut (general intestinal permeability). Start with colostrum (Grade B, OTC, human data). Consider larazotide if permeability is the primary concern and you have access through a practitioner. BPC-157 is a Tier 3 option after foundations are in place. Before any peptide, ensure L-glutamine (5 to 10 grams daily) and zinc carnosine (75 mg twice daily) are in your protocol. These traditional supplements have human trial data and cost a fraction of peptide therapy.
Ulcerative colitis. KPV targets the NF-kB pathway that drives UC inflammation. BPC-157 addresses the mucosal damage component. Both are preclinical only. Neither replaces standard UC treatment (mesalamine, biologics, JAK inhibitors). Discuss with your gastroenterologist.
Crohn's disease. BPC-157 has the most relevant preclinical evidence (TNBS colitis model). KPV addresses the inflammatory component. Colostrum provides mucosal immune support. See our Crohn's disease supplements guide for the full evidence-based stack.
Celiac disease (persistent symptoms on GFD). Larazotide is the most targeted option, with Phase 2b data showing symptom reduction at 0.5 mg. Colostrum provides additional mucosal support. Both should complement a strict gluten-free diet, not replace it.
NSAID-induced gut damage. Colostrum has human data (Playford 2001) showing reduced NSAID-induced permeability. BPC-157 has consistent animal data across NSAID damage models. If you cannot stop the NSAID, colostrum is the first-line peptide option.
Post-antibiotic gut repair. LL-37 addresses the antimicrobial defense gap that antibiotics create, though evidence is entirely mechanistic. Colostrum provides immunoglobulin support. Practical approach: optimize vitamin D (to boost endogenous LL-37), add colostrum, and prioritize probiotics.
Short bowel syndrome. GLP-2 (teduglutide/Gattex) is the only FDA-approved option with Grade A evidence. This requires specialist gastroenterology care.
Peptides vs Traditional Gut Supplements
Before spending $150 or more per month on peptide therapy, consider whether traditional gut supplements might address your needs at a fraction of the cost, with more human evidence to back them up.
L-glutamine is the primary fuel source for enterocytes (intestinal lining cells). Zhou et al. (2019) showed that 0.5 g/kg/day of L-glutamine reduced intestinal permeability in patients with Crohn's disease in remission. That is a human RCT. BPC-157, for all its impressive animal data, cannot match that. L-glutamine costs roughly $15 to $30 per month. See our L-glutamine dosing guide for protocols.
Zinc carnosine protects the gastric and intestinal mucosa through a distinct mechanism: it adheres to damaged mucosal tissue and promotes healing locally. Mahmood et al. (2007) demonstrated that zinc carnosine reduced NSAID-induced intestinal permeability by threefold in a human RCT. Again, human data that outranks BPC-157's preclinical results.
Bovine colostrum bridges the gap between traditional supplements and peptide therapy. It contains bioactive peptides (lactoferrin, PRPs) alongside immunoglobulins and growth factors. Human studies support its use for gut permeability. Cost ranges from $30 to $80 per month.
The honest recommendation: build your gut healing protocol on L-glutamine and zinc carnosine first (Tier 1). Add colostrum as Tier 2. Consider BPC-157, KPV, or larazotide as Tier 3 options only after foundations are solid and under practitioner guidance. This approach respects the evidence hierarchy and avoids the common mistake of reaching for the most exotic option while neglecting the fundamentals.
Combining Gut Peptides: Stacking Protocols
Practitioner communities have developed combination ("stacking") protocols based on complementary mechanisms. These are practitioner-derived, not clinically validated. No study has tested any peptide combination for gut healing in humans.
BPC-157 + KPV is the most common gut peptide stack. The rationale is straightforward: BPC-157 repairs damaged tissue through angiogenesis while KPV controls the inflammation that caused the damage. Addressing both pathways simultaneously makes pharmacological sense, even if no trial confirms it.
BPC-157 + larazotide + KPV is an emerging "gut triple" approach targeting three distinct pathways: tissue repair, barrier restoration, and inflammation control. Some compounding pharmacies now offer combination capsules containing all three. The appeal is mechanistic comprehensiveness. The limitation is complete absence of safety or efficacy data for the combination.
Cycling protocols. Most practitioners recommend 4 to 8 weeks on peptide therapy followed by 2 to 4 weeks off. The rationale is to avoid receptor desensitization and to assess whether improvements persist after discontinuation. This cycling approach is empirical, not evidence-based.
What not to combine. There is no established contraindication between these gut peptides, but the interaction between any of them and biologic IBD drugs (adalimumab, infliximab, vedolizumab, ustekinumab) is completely unstudied. If you are on biologics for IBD, do not add peptides without explicit discussion with your gastroenterologist.
Safety, Legal Status, and Access (2026 Update)
The peptide regulatory landscape shifted significantly in February 2026, when the FDA reclassified several compounds under its new Category system.
Category 1 (legally compoundable with prescription). BPC-157 and KPV are now Category 1 compounds. This means licensed compounding pharmacies can produce them with a valid prescription from a licensed provider. This is a substantial improvement over the previous gray market situation where patients purchased "research-grade" peptides of uncertain quality.
OTC availability. Colostrum is the only option on this list available without a prescription. It is classified as a dietary supplement and sold through mainstream supplement retailers.
Prescription pharmaceutical. Teduglutide (Gattex) is an FDA-approved prescription drug for short bowel syndrome. It is available only through specialty pharmacies and requires specialist prescribing.
Research compounds only. Larazotide and LL-37 remain research compounds. They are not FDA-approved, not reclassified under Category 1, and not available through standard compounding pharmacies. Access is limited to research suppliers or specialty compounding sources.
Drug interaction warnings. No peptide on this list has been studied in combination with standard IBD medications (biologics, immunomodulators, corticosteroids). The interaction profile is unknown. Peptides that modulate NF-kB (KPV) or immune function (colostrum immunoglobulins) could theoretically interact with immunosuppressive therapy, though this is speculative. Conservative approach: inform your prescribing physician about any peptide use.
Frequently Asked Questions
Which peptide is best for leaky gut?
Larazotide acetate is the only peptide that directly targets intestinal permeability by blocking the zonulin receptor and restoring tight junction integrity. It showed positive results in a Phase 2b trial for celiac patients (Leffler et al. 2015). BPC-157 is the next best option for general gut repair, with extensive animal evidence for mucosal healing through angiogenesis and VEGF stimulation. For most people, starting with L-glutamine and zinc carnosine (both with human RCT data) before moving to peptide therapy is the evidence-based approach.
Can I combine BPC-157 and KPV for gut healing?
BPC-157 and KPV target complementary mechanisms: tissue repair (BPC-157) and inflammation control (KPV). Some practitioners combine them for this reason, and the pharmacological rationale is sound. No clinical trial has studied this combination. The interaction profile and combined safety profile are unknown. If you pursue this approach, work with a practitioner experienced in peptide protocols and start with one peptide before adding the second.
What happened to larazotide and why did its Phase 3 trial fail?
The CedLara Phase 3 trial was discontinued by 9 Meters Biopharma in 2022. The failure was statistical, not pharmacological. The primary endpoint was difficult to measure reliably, and the trial was likely underpowered for the expected effect size. The Phase 2b trial at 0.5 mg had shown significant symptom reduction in celiac patients on a gluten-free diet. Fasano's zonulin research, which underpins larazotide's mechanism, remains well-established and widely cited. The drug simply has not found its way through the clinical trial gauntlet, which is different from saying it does not work.
Are there any gut peptides with human clinical trial data?
Yes, three. Teduglutide (GLP-2 analog) has the strongest evidence, with multiple RCTs and FDA approval for short bowel syndrome. Larazotide has a positive Phase 2b trial in celiac disease. Colostrum has multiple human studies showing reduced intestinal permeability, including the Playford 2001 study on NSAID-induced damage. BPC-157 and KPV have only animal data. LL-37 has only mechanistic evidence for gut applications.
What is the difference between BPC-157 and KPV for gut inflammation?
BPC-157 is primarily a tissue repair peptide. It promotes new blood vessel formation (angiogenesis), modulates the NO system, and supports mucosal healing. It also has anti-inflammatory effects but these are secondary to its repair function. KPV is primarily an anti-inflammatory peptide. It enters epithelial cells through the PepT1 transporter and inhibits NF-kB, the master switch for inflammatory gene expression. If your gut problem is driven by active inflammation (as in IBD flares), KPV is more mechanistically targeted. If your gut problem involves tissue damage and poor healing, BPC-157 is more relevant.
How do peptides compare to L-glutamine and zinc carnosine for gut repair?
L-glutamine and zinc carnosine have something most gut peptides lack: human clinical trial data. L-glutamine fuels enterocytes and reduced intestinal permeability in a Crohn's remission RCT (Zhou 2019). Zinc carnosine reduced NSAID-induced gut damage by threefold in a human RCT (Mahmood 2007). Both cost $15 to $30 per month. BPC-157 has stronger preclinical evidence for mucosal repair but no human trials and costs $100 or more per month. The evidence-based sequence: start with glutamine and zinc carnosine, add colostrum, then consider peptides as Tier 3 under practitioner guidance. For more on the foundational approach, see our best supplements for autoimmune disease guide.
The Bottom Line
The gut peptide landscape in 2026 includes one FDA-approved option (teduglutide for SBS), two newly compoundable peptides (BPC-157 and KPV under Category 1), one with positive Phase 2b data but no commercial product (larazotide), one available OTC with human evidence (colostrum), and one that remains primarily a research compound (LL-37).
For most people dealing with gut permeability, inflammation, or mucosal damage, the practical sequence looks like this: build a foundation with L-glutamine, zinc carnosine, and dietary changes first. Add colostrum as an accessible, evidence-supported next step. Consider BPC-157 or KPV under practitioner guidance as advanced options after foundations are in place. This respects the evidence hierarchy without dismissing the genuine promise of peptide therapeutics.
If you are dealing with an autoimmune condition that involves gut dysfunction, our quiz can help identify which interventions fit your specific situation, from foundation supplements to advanced peptide protocols. For the broader peptide landscape beyond gut health, see our peptides for autoimmune disease hub.
This article is for educational purposes only and does not constitute medical advice. Peptides other than teduglutide are not FDA-approved for gut healing. Do not replace standard IBD treatment with peptide therapy. Discuss any peptide use with your gastroenterologist, especially if you take immunosuppressants or biologic medications.